Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference

NEW YORK, March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck^® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will be prominently featured at Digestive Disease Week (DDW) 2025, the world's premier meeting for gastroenterologists and other digestive disease professionals, to be held in May.

The campaign highlights EsoCheck's outstanding performance in nearly 30,000 patients to date, including a pristine safety record, high patient satisfaction, and a very high success rate for a procedure performed in an office or health fair setting in less than three minutes. Published data demonstrates that samples collected with EsoCheck, when analyzed with Lucid's EsoGuard^® Esophageal DNA Test, detected esophageal precancer, including short segment disease, with an unprecedented negative predictive value (NPV) of approximately 99%.

"April is Esophageal Cancer Awareness Month, a sober reminder that approximately 16,000 Americans tragically die each year from this highly lethal, but now preventable, cancer," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "Thanks to our modern groundbreaking technologies, EsoGuard and EsoCheck, the future for esophageal cancer prevention is very bright. A substantial body of published, peer-reviewed clinical evidence now demonstrates EsoGuard's unprecedented performance as a noninvasive triage tool to detect esophageal precancer so it can be monitored and treated before cancer develops. EsoCheck's ability to perform precisely targeted and protected sampling plays a critical role in this outstanding performance."

Dr. Aklog added, "Brillo pad-like sponge-on-a-string (SOS) devices, essentially unchanged in design since they were introduced in the early 1990s, are relics of the past which indiscriminately scrape cells from the stomach, esophagus and mouth. Their poor performance, especially in patients with small patches of precancer, is attributable to their inability to target the specific area of the esophagus where precancer and cancer occur. SOS devices have also been plagued by serious device failures and complications, leading to multiple Class II FDA recalls and product withdrawals. In stark contrast, EsoCheck's soft and gentle, targeted and protected approach to noninvasive esophageal cell collection has resulted in a pristine safety record with no device failures after nearly 30,000 procedures."

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

SOURCE Lucid Diagnostics